Evidence map›Paper›PMID 38454095›Full record

ArticleScientific reports2024

Evaluation of the mosquitocidal efficacy of fluralaner, a potential candidate for drug based vector control.

Harish Kumar Shah, Vaishnavi Srinivasan, Shakila Venkatesan, Vijayakumar Balakrishnan, Sadanandane Candasamy, Nisha Mathew, Ashwani Kumar, Vijesh Sreedhar Kuttiatt

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Harish Kumar ShahICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Vaishnavi SrinivasanICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Shakila VenkatesanICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Vijayakumar BalakrishnanICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Sadanandane CandasamyICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Nisha MathewICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Ashwani KumarICMR-Vector Control Research Centre, Puducherry, 605 006, India.
Vijesh Sreedhar KuttiattICMR-Vector Control Research Centre, Puducherry, 605 006, India. vijeshvcrc.icmr@gmail.com.
Vector Control Research Centre · INSaveetha University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vector control is a key intervention against mosquito borne diseases. However, conventional methods have several limitations and alternate strategies are in urgent need. Vector control with endectocides such as ivermectin is emerging as a novel strategy. The short half-life of ivermectin is a limiting factor for its application as a mass therapy tool for vector control. Isoxazoline compounds like fluralaner, a class of veterinary acaricides with long half-life hold promise as an alternative. However, information about their mosquitocidal effect is limited. We explored the efficacy of fluralaner against laboratory reared vector mosquitoes-Aedes aegypti, Anopheles stephensi, and, Culex quinquefasciatus. 24 h post-blood feeding, fluralaner showed a significant mosquitocidal effect with LC

Indexed as

AedesAnophelesCulexInsecticidesIsoxazolesAnimalsIvermectinLarvaMosquito VectorsPlant ExtractsA1443 compoundInsecticidesIsoxazolesIvermectinPlant ExtractsDrug based vector controlEndectocideFluralanerLife history characteristicsMosquitocidal effect

Identifiers

PMID38454095
PMCPMC10920869
OpenAlexW4392561931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.